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Pascal Thomas, MD, Federico Venuta, MD,¶ and the European Society of Thoracic Surgeons Thymic
Questionnaire Working Group
Introduction: Management of thymoma has largely been based on
single-institution retrospective, observational studies. The European
Society of Thoracic Surgeons (ESTS) Thymic Working Group has
investigated the current practice among ESTS members.
Methods: A questionnaire divided into seven sections with 24
questions was designed, and it was delivered to ESTS members.
Results: Forty-four centers replied to the questionnaire. The results
indicate that there is a general agreement concerning (1) the value of
computed tomography scan for preoperative assessment; (2) the
uselessness of a routine histologic confirmation before surgery; (3)
the role of the World Health Organization classification; (4) the
importance of complete and extended resection; (5) the role of
surgery for recurrent disease; and (6) the need of a multidisciplinary
team, including thoracic surgeons, pathologists, medical, and radi-
ation oncologists. On the other hand, there is still a considerable
debate about (1) the role of positron emission tomography scan for
preoperative assessment; (2) a consistent and reliable staging sys-
tem; (3) the usefulness of postoperative treatments for stages II and
III diseases; (4) the management of type C thymoma; and (5) the
role of extrapleural pneumonectomy for stage IVA thymoma.
Conclusions: The survey provides a large, multiinstitutional over-
view of the clinical practice in the management of thymic tumors by
ESTS members. Responses show some areas of agreement along
with several areas of controversy. It is conceivable that a consequent
step forward will be the creation of a collaborative effort within the
ESTS and with other organizations for the creation of standard
recommendations and guidelines for the management of thymic
malignancies.
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(J Thorac Oncol. 2011;6: 614–623)
Thymoma is the most frequent epithelial tumor in theanterior mediastinal compartment in adults, with an over-
all incidence of 0.15 cases per 100,000 (National Cancer
Institute Surveillance, Epidemiology and End Results pro-
gram).1 Because of the indolent course and sporadic occur-
rence of these lesions, management has largely been based on
single-institution retrospective, observational studies. Despite
the large body of literature, no uniformly accepted guidelines
are available so far. Complete surgical resection, when fea-
sible, is currently considered the gold standard; however, the
role of chemo-radiotherapy (RT), histology, and staging is
still to be clearly defined. The European Society of Thoracic
Surgeons Thymic Working Group (ESTS-TWG) distributed
an electronic survey among the members of the Society to
collect an overview of current thymoma management.
MATERIALS AND METHODS
An e-mail was sent to all ESTS members encouraging
the ESTS community to join the ESTS thymic group and its
activities indicating the intention to launch the questionnaire.
Questionnaire Design
The questionnaire was designed by the ESTS-TWG
steering committee and was delivered by e-mail to ESTS
members who were interested to participate to retrospective
and prospective studies. The questionnaire included 25 points
organized in seven sections:
Y Volume of activity
Y Preoperative assessment
Y Histology and staging system
Y Extent of surgical resection
Y Pre- and postoperative treatment of stages II and III
diseases according to the Masaoka classification
Y Treatment of stage IV tumors, recurrence, and type C
thymoma
Y Local multidisciplinary organization and logistics
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The centers were also allowed to add personal com-
ments after each question to clarify their answer and imple-
ment understanding.
After 2 months, 52 centers showed interest, and 44
answered the survey. The contributors were primarily from
not only academic hospitals (N  29, 66%) but also commu-
nity hospitals, and private institutions were well represented.
The geographical distribution is presented in Table 1: 33 were
from Europe, four from Asia (Israel, one; Japan, one; Saudi
Arabia, one; and Turkey, one), five from the United States,
one from Canada, and one from South America (Brazil).
Most of the European countries were represented: Italy (14),
Austria (two), France (two), Germany (two), Poland (four),
Spain (two), Belgium (one), Czech Republic (one), Greece
(one), Portugal (one), Netherland (one), the United Kingdom
(one), and Switzerland (one). The analysis was performed
using basic statistics. Proportion differences were tested us-
ing the 2 method (Fisher’s exact test when appropriate).
Statistical analysis was performed using STATISTICA (Stat-
soft, Italy, release 7.1) software.
RESULTS
The results are reported for each section separately,
referring to each of the 25 questions.
Section 1: Volume of Activity and Time Period
(Table 2)
1. Howmany thymoma resections are performed at your
center yearly? 1 to 5; 6 to 10; 11 to 20; and more than 20.
2. What is the overall number of patients operated at
your center? less than 20; 21 to 50; 51 to 100; 101 to
300; and more than 300.
3. In how many years? less than 10; 11 to 20; and more
than 20.
Half of the centers (N  23.52%) perform from 5 to 10
thymoma resections per year; one third (N  14, 32%) from
10 to 20, four centers (9%) more than 20, and three (7%)
perform less than five resections per year. Most of the centers
(16/18.89%) performing more than 10 resections per year are
academic institutions. Sixteen centers (36%) have performed
between 50 and 100 thymoma resections. Thirty percent (N
13) have performed between 20 and 50 resections; 25% (N
11) between 100 and 300; and three centers (7%) have
performed more than 300 operations. Seven centers (16%)
had a long tradition of thymoma surgery (more than 20
years), 16 (36%) have been practicing thymoma surgery for
10 to 20 years, and 21 centers (48%) have started in the last
decade. Therefore, this survey covers a wide range of expe-
riences from different centers in different countries from all
over the world, in terms of the number of procedures per year,
the overall number of operations, and length of activity.
Section 2: Preoperative Assessment (Table 3)
1. Do you perform total body computed tomography
(CT) scan before surgery? All centers rely on CT for
preoperative evaluation, but only 19 (43%) use total
body CT scan. The remaining 25 centers consider either
chest or chest  upper abdomen CT scan sufficient.
This confirms what reported in the international litera-
ture2–4: chest CT scan with intravenous contrast admin-
istration is the radiographic examination of choice for
the evaluation of all anterior mediastinal masses. The
radiological features are diagnostic, especially for early-
stage lesions and when calcifications are associated;
TABLE 1. Geographic Distribution of the Respondents
Country Respondents (No.)
Europe 33
Italy 14
Poland 4
Austria 2
France 2
Germany 2
Spain 2
Belgium 1
Czech Republic 1
Greece 1
Portugal 1
Switzerland 1
The Netherlands 1
United Kingdom 1
The United States and Canada 6
The United States 5
Canada 1
Asia 4
Israel 1
Japan 1
Saudi Arabia 1
Turkey 1
South America 1
Brazil 1
TABLE 2. Volume of Activity among the Different Centers
Question
Response
Count
Response
%
1. How many thymoma resections are
performed at your center yearly?
1–5 3 7
5–10 23 52
10–20 14 32
20 4 9
2. What is the total number of patients with
thymoma operated at your center?
20 1 2
20–50 13 30
50–100 16 36
100–300 11 25
300 3 7
3. In which time period?
10 yr 21 48
10–20 yr 16 36
20 yr 7 16
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problems of differential diagnosis may occur at more
advanced stages, when local aggressiveness may mimic
lymphoma or germ cell tumors. The use of abdominal
CT scan may be indicated in the latter situation or for
accurate staging before induction treatment.
2. Do you use positron emission tomography (PET) (or
PET/CT) scan for preoperative assessment? The ex-
perience of the different centers about the use of PET or
integrated PET/CT scan in patients with thymoma was
evenly distributed: 22 (50%) centers reported to use
PET, and 22 (50%) do not use it. This probably reflects
the slowly increasing availability of PET and its role in
the diagnosis of thoracic malignancies. Only one center
indicates that the reason why they do not use PET is
related to the unavailability of the equipment at their
institution. Many centers indicate that they routinely use
PET to assess response to induction therapy before
planning surgical resection. Others comment that they
use PET only on a selective basis, depending on stage.
One center indicates that they use PET only when
pleural dissemination is suspected. No center mentioned
the potential role of standard uptake value in their
comments.
3. Do you always try to obtain histological confirma-
tion before surgical resection? The answers to this
question are quite interesting. Forty centers (91%) do
not routinely look for histological confirmation when
thymoma is suspected. This apparently does not match
with the current general opinion about always attempt-
ing to obtain diagnosis before surgical resection. As
mentioned before, there was a possibility to add com-
ments; the most frequent addendum was that in case CT
scan strongly suggests thymoma (small, resectable, cap-
sulated lesions with no radiological sign of invasion) or
when myasthenia gravis is associated, no preoperative
histological diagnosis should be required. One center
stated that they always require intraoperative frozen
sections before proceeding to resection. In few cases, it
has been also stated that complete resection of a small
mediastinal mass through a minimally invasive ap-
proach is appropriate even in case of lymphoma, as it
provides adequate material for the pathologist. Other
comments reported the potential increased risk of tumor
spread through the needle biopsy site or in the pleura
during video-assisted thoracic surgery. Most of the
comments stated that surgical biopsy should be pre-
ferred (anterior mediastinotomy or video-assisted tho-
racic surgery) and should be performed only if lym-
phoma is suspected at CT, when neoadjuvant treatment
is to be planned, or the lesion looks unresectable.
Section 3: Histologic Classification and Staging
(Table 4)
1. Do you use the World Health Organization (WHO)
pathologic classification? If not which classification
do you use? All centers except one (98%) use the WHO
histologic classification proposed in 19995 and updated
in 20046; this system classifies thymoma on the base of
morphology and lymphocyte to epithelial cells ratio
using letters and numbers (A, AB, B1, B2, B3, and C).
C tumors have been recently completely separated and
are currently considered as a different entity.7 It is,
therefore, clear that the WHO classification has gained
wide acceptance as the standard histologic classification
for thymic malignancies. The single center reporting not
to use the WHO system did not provide any information
about what classification they currently use.
2. Do you use the Masaoka staging system? If not, what
system are you currently using? The centers were
asked to choose among four proposed staging systems
including the standard Masaoka system,8 the modified
Masaoka-Koga,9 the tumor, nodes, and metastasis
(TNM) system,10 and the Groupe d’Etude des Tumeurs
Thymique (GETT) system.11 Most (33 centers, 75%)
stated to favor the standard Masaoka staging system,
which divides thymoma into four stages based on clini-
cosurgical criteria of invasion (stages I–IV). Of the
remaining 11 centers, eight reported to use the modified
Masaoka-Koga system (stage II and stage III are di-
vided into A and B subgroups) (one in Germany,
France, Austria, and Portugal each and two in Italy and
TABLE 3. Preoperative Assessment
Question
Response
Count
Response
%
1. Do you perform total body CT scan
before resection?
Yes 19 43
No 25 57
2. Do you use PET (or integrated PET/CT)
scan in patients with thymoma?
Yes 22 50
No 22 50
3. Do you always try to obtain histologic
confirmation before surgical resection?
Yes 4 9
No 40 91
PET, positron emission tomography; CT, computed tomography.
TABLE 4. Histologic Classification and Staging
Question
Response
Count
Response
%
Do you use the WHO pathologic classification?
Yes 43 98
No 1 2
Do you use the Masaoka staging system?
Yes 33 75
No 11 25
If not, which staging system do you use?
Masaoka-Koga 8
TNM 2
GETT 1
WHO, World Health Organization; TNM, tumor, node, and metastasis; GETT,
Groupe d’Etude des Tumeurs Thymique.
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the United States each). Two centers indicated that they
still use the TNM staging system either routinely or on
some occasion (one in Italy and one in Switzerland),
and one (France) reported that they use the GETT
system that takes into consideration also the extent and
completeness of resection. It may, therefore, be con-
cluded that there is still no uniform consensus about the
optimal staging system in patients with thymoma.
Section 4: Extent of Surgical Resection (Table 5)
1. Do you strive to obtain complete resection even if it
requires extension to neighboring organs?
2. Do you extend the resection to the pericardium,
lung, and great vessels for stage III thymoma?
All centers but two (95%) agree that complete resection
is crucial and should include all the adjacent structures, if
they are involved and if they are technically resectable (and
reconstructable, when required). Extended resections, includ-
ing pericardium, lung, diaphragm, and great vessels are often
feasible; however, only 42 (95%) centers reported to perform
them. When asked to make comments, many of them appro-
priately indicate notable exceptions to extended resections:
three centers indicate that they do not perform resection of the
great vessels (without stating what great vessels), and they
prefer to leave residual disease to be treated with postopera-
tive RT. Also, some others stated that they do not resect both
phrenic nerves in case of bilateral involvement. From the
present survey, it appears a general agreement on the need to
achieve complete resection when technically feasible; con-
cern exists about invasion of the great vessels and bilateral
phrenic nerve involvement.
Section 5: Pre- and Postoperative Treatment in
Stage II Thymic Tumors (Table 6)
1. Do you administer adjuvant treatment in Masaoka
stage II thymoma? If yes, what type of treatment?
Twenty-seven centers (61%) report that they tend to
administer postoperative treatment at this stage. They
use postoperative RT in most of the cases; only three
centers use combined radio and chemotherapy. Twenty
of them routinely administer postoperative treatment;
the others consider it on a case-by-case basis related to
histology (only in B2–B3 and C types), staging (only in
case of stage IIB according to the modified Masaoka-
Koga staging system), or completeness of resection
(incomplete resections are treated). Seventeen centers
(39%) clearly stated not to use any postoperative treat-
ment after resection of stage II thymoma in any case,
independently from the pathological report, invasion of
the capsule, or potential incomplete resection. Thus, it
seems that this issue still poses many important ques-
tions to be addressed.
2. Do you administer induction chemotherapy for stage
III thymoma? Induction chemotherapy is used by the
majority of the centers (33 centers, 75%), whereas 11
do not. It is not clear from the survey whether at these
centers they proceed with surgery upfront or whether
they use RT to downstage the tumor. The centers with
more experience tend to use induction.
3. Do you administer postoperative chemotherapy, RT,
or a combination of both after resection of stage III
thymoma? All centers but three use postoperative treat-
ments after resection of stage III thymoma. Three cen-
ters do not use any kind of postoperative treatment in
case of macro- and microscopic complete resection or
indicate postoperative therapy only in case of incom-
plete resection. Twenty-nine centers use either chemo-
therapy or RT without stating in their comments how do
they select them. Chemotherapy alone was administered
only at three centers, whereas postoperative RT alone
was used in 26. Finally, 25 centers use an association of
radio- and chemotherapy; some centers reported that
they use it based on WHO histology (B2–B3 and C
types). There is clearly a heterogeneous approach to
postoperative treatment after resection of invasive
TABLE 5. Extent of Surgical Resection
Question
Response
Count
Response
%
Do you strive to obtain a total resection even in
case of anticipated extended resection to
neighboring structures?
Yes 42 95
No 2 5
Do you perform extended resection of the
pericardium, lung, diaphragm, and great
vessels in case of stage III thymoma?
Yes 42 95
No 2 5
TABLE 6. Induction and Adjuvant Treatments in Stages II
to III Thymomas
Question
Response
Count
Response
%
Do you use induction treatment for stage III
thymoma?
Yes 33 75
No 11 25
Do you administer adjuvant treatment for stage
II thymoma?
Yes 27 61
No 17 39
Do you administer adjuvant chemotherapy only
for stage III thymoma?
Yes 3 7
No 41 93
Do you administer adjuvant radiotherapy only
for stage III thymoma?
Yes 26 59
No 18 41
Do you administer adjuvant chemo-radiotherapy
(together) for stage III thymoma?
Yes 25 57
No 19 43
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(stage III) thymoma; most centers administer RT or
radio-chemotherapy, whereas chemotherapy alone is
rarely used.
Section 6: Treatment of Stage IV Thymoma,
Recurrences, and Type C Tumors (Table 7)
1. Do you administer induction chemotherapy for stage
IVA thymoma?
2. Do you perform extrapleural pneumonectomy (EPP)
for stage IVA thymoma? Treatment of advanced thy-
moma (stage IVA) with pleural dissemination is still
controversial. Most of the centers (38.86%) administer
induction chemotherapy at this stage with subsequent
surgical resection of the pleural implants. In case of
extended pleural and lung involvement, EPP or pleu-
rectomy/decortication (P/D) has been advocated by
some authors. From our survey, 18 centers (41%) agree
to perform EPP or P/D in case of major pleural involve-
ment to achieve complete resection. Only one group
performed intrapleural hyperthermic chemotherapy af-
ter surgical resection. The remaining 26 centers (59%)
do not consider EPP indicated in this setting.
3. In case of locoregional recurrence, do you think
surgery should be indicated? The questionnaire in-
cluded one question about thymoma recurrence and the
potential surgical treatment. Forty centers (91%) agree
that recurrence should be removed when complete re-
section is feasible; some of them reported to have
already performed multiple subsequent resections in
case of repeated recurrence. Many centers added in their
comments that a correct patient selection is crucial and
that they proceed to resection only when complete
resection may be anticipated.
4. Do you treat type C thymoma (thymic carcinoma)
differently from other histologic subtypes? The re-
sults of the survey indicate that the majority of the
centers (N 23.52%) use a different treatment policy in
case of type C thymoma. In particular, some of them
added in their comments that, with this histology, they
always administer induction chemotherapy before sur-
gery, even in case of stage I disease; others simply
stated to use a different chemotherapeutic regimen.
Section 7: Multidisciplinary Organization and
Logistics (Table 8)
1. Do you have a dedicated pathologist for thymic
malignancies?
2. Do you have a dedicated medical oncologist for
thymic malignancies?
3. Do you have a dedicated radiation oncologist for
thymic malignancies?
Thirty-six centers (82%) indicated that they have a
dedicated pathologist, 37 (84%) a dedicated medical oncol-
ogist, and 29 (66%) a dedicated radiation oncologist for
thymic tumors. Some centers added that they have a dedi-
cated tumor board to discuss management of thymic neo-
plasms.
High-Volume versus Low-Volume Centers
Further analysis was undertaken stratifying the sur-
veyed centers by the volume of activity. Two groups were
identified: those performing more than 10 thymoma resec-
tions per year (high-volume group, N  18) and those
performing less than 10 thymoma resections per year (low-
volume group, N  26); the answers in the two groups were
compared (Table 9), including the following variables: the
use of standard Masaoka staging, the use of PET scan,
postoperative treatment at stage II, the administration of
induction treatment at stage III, postoperative treatments at
stage III (further divided into chemotherapy, RT, and com-
bined radio-chemotherapy), the need to pursue complete
resection and extended resections to neighboring structures,
the use of induction therapy and EPP at stage IV, a different
policy to treat type C thymoma, and the presence of a
dedicated team. The results of our analysis indicate that
high-volume centers less frequently use combined radio-
chemotherapy after resection of stage III thymoma (p 0.01)
and less frequently use postoperative treatment after resection
TABLE 7. Treatment of Stage IV, Recurrence, and Type C
Tumors
Question
Response
Count
Response
%
1. Do you administer induction chemotherapy for
stage IV thymoma?
Yes 38 86
No 6 14
2. Do you consider extrapleural pneumonectomy for
stage IV thymoma?
Yes 18 41
No 26 59
3. In case of locoregional recurrence, do you think
surgery may be indicated?
Yes 40 91
No 4 9
4. Do you treat type C thymoma differently?
Yes 23 52
No 21 48
TABLE 8. Multidisciplinary Organization
Question
Response
Count
Response
%
Do you have a dedicated pathologist?
Yes 36 82
No 8 18
Do you have a dedicated medical
oncologist?
Yes 37 84
No 7 16
Do you have a dedicated radiation
oncologist?
Yes 29 66
No 15 34
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of stage II thymoma (p  0.03), when compared with
low-volume centers.
DISCUSSION
The present survey provides insights on the manage-
ment of thymic malignancies coming from 43 centers belong-
ing to the ESTS community. The analysis supports the need
of an extended discussion and clarification on several points
to achieve a uniform approach.
The results of the questionnaire indicate that there is a
general agreement concerning the following issues: (1) the
role of CT scan; (2) the uselessness of a routine histologic
confirmation before surgery; (3) the role of the WHO classi-
fication; (4) the need to achieve complete resection extending
surgery to the neighboring organs, if required; (5) the role of
surgery for recurrent disease; and (6) the positive role of a
multidisciplinary team including thoracic surgeons, patholo-
gists, medical, and radiation oncologists to approach thymic
tumors in a dedicated tumor board. On the other hand, there
is still a considerable debate about (1) the role of PET scan
for preoperative assessment; (2) the staging system; (3) the
administration of postoperative treatments at stages II and III;
(4) the management of type C thymoma; and (5) the role of
EPP at stage IVA.
Thymic neoplasms are rare; the large body of literature
available on this topic is based on retrospective, mostly
single-institutional, observational studies. Several strategic
decisions are still controversial and are often based on per-
sonal experience and individual practice. There are no guide-
lines concerning optimal management. For this reason, our
survey may represent a good platform to start a collaborative
effort and provide insights into those problems still awaiting
a definitive answer.
The questionnaire was grouped into seven sections,
each of which covers a particular aspect in thymoma man-
agement; each section deserves discussion.
1. Volume of activity and time period: This section was
designed to obtain a snapshot about the type of
institutions involved in the survey and to improve
interpretation of the results. Interestingly, all types
of institutions were present including well-known
word-recognized centers of excellence, academic Insti-
tutions, and smaller hospitals. This surely adds strength
to our study and provides support to extend the results
to the scientific community.
2. Preoperative assessment: There is a general agreement
that the new generation CT scans offers a reliable and
appropriate diagnostic tool. The potential extension of
the examination beyond the chest is still debated; more
than half of the centers perform total body CT scan,
which may be of help to differentiate thymoma from
other mediastinal disorders, in particular lymphoma.
Despite the little evidence in the literature about the
value of PET or integrated PET-CT scan,12,13 half of the
centers does use PET scan, although mostly on a selec-
tive basis, with three major indications: (a) potentially
invasive thymoma, (b) pleural dissemination, and (c)
assessment of response after induction therapy. It
sounds clear that the role of PET scan in the manage-
ment of patients with thymoma needs to be discussed,
but this will certainly require prospective studies.
Histologic confirmation before resection was not con-
sidered crucial at almost all centers. When the lesion is
small, capsulated, calcified, or cystic, with radiological
characteristics clearly excluding lymphoma, and if the
clinical presentation is not suggestive of lymphoma, all
centers agree to proceed directly to surgery; the pres-
ence of myasthenia gravis also helps in this direction.
Histology is required for invasive lesions, before induc-
tion therapy, if the tumor is clearly unresectable or
when the radiological features do not allow to exclude
other mediastinal disorders requiring a different ap-
proach. The potential pleural or transthoracic seeding
during biopsy is also a major concern, although this fear
is not substantiated in the literature.14
3. Histologic classification and staging: There is a general
agreement that the WHO classification proposed should
be worldwide accepted. This assumption is clearly sup-
ported by the international literature, reporting it as an
independent prognostic factor.15–17 Only one center
stated that they do not use it without reporting their
system. Concerning the staging system, the question-
naire proposed four options: the standard Masaoka
system, the modified Masaoka-Koga, the TNM, and the
GETT classification. The standard Masaoka is still used
in most of the cases, followed by the modified
Masaoka-Koga. The TNM and GETT classifications are
used only by three centers. Also, this point is consistent
with the international literature.18–22 Nevertheless, as
TABLE 9. Comparison of Different Responses in High-
Volume (N  18) vs. Low-Volume (N  26) Groups
Variables
High-
Volume
Group
Low-
Volume
Group
Yes No Yes No
Masaoka staging 14 4 19 7
Use of PET scan 10 8 16 10
Total resection 18 0 24 2
Extended resection 17 1 25 1
Postoperative treatment in stage II 7 11 20 6
Preoperative treatment in stage III 15 3 18 8
Postoperative treatment in stage III
Chemotherapy 0 18 3 23
Radiotherapy 11 7 10 16
Chemo-radiotherapy 4 14 14 12
Preoperative chemotherapy in stage IV 16 2 22 4
EPP in stage IV 8 10 10 16
Different policy in type C thymoma 12 6 11 15
Dedicated pathologist 16 2 19 7
Dedicated medical oncologist 15 3 21 5
Dedicated radiation oncologist 13 5 16 10
PET, positron emission tomography; EPP, extrapleural pneumonectomy.
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we will see in the analysis of the following section, both
histology and staging, although uniformly accepted, do
not uniformly impact treatment modalities, and poten-
tially also on long-term results. Thus, the WHO and
Masaoka classifications should be the object of prospec-
tive studies to improve their role in patient and treat-
ment modality selection.
4. Extent of surgical resection: Complete resection is clearly
the most important prognostic factor and should be aimed
even if the neighboring organs are involved. This also
appear from the international literature,18,19,23–25 and it is
so important that the GETT staging system has included
this variable. Extended resections are often feasible and
associated with satisfactory survival rates26–28; the lung,
great vessels, and, in particular, the superior vena cava,
the pericardium, and the diaphragm are to be removed
along with the tumor when they are involved and if the
required reconstruction is feasible. Nevertheless, some
concern still exists about resection and reconstruction of
the great vessels. Some centers reported that they prefer
leaving residual tumor and refer the patient for adjuvant
treatment. It is not clear from the answers and com-
ments whether this concern is restricted only to the
ascending aorta and main pulmonary artery or whether
it is also referred to the superior vena cava. The other
exception is referred to bilateral involvement of both
phrenic nerves, in the fear of postoperative respiratory
failure and ventilator dependence; this is even more
crucial in myastenic patients; in such cases, incomplete
resection on one nerve is advisable.
5. Pre- and postoperative treatment for stage II thymoma
and stage III thymoma: This is the most controversial
issue coming out from our survey, and it echoes the
debate in the literature.19,29–33 In stage II thymoma,
although 60% of the surveyed centers administer RT
after surgical resection, most of them stressed that the
indication to RT should be raised selectively, based on
(a) histology (only B2, B3, and C types), (b) the
perceived completeness of resection by the surgeon, or
(c) staging according to the Masaoka-Koga system. The
subdivision of stage II into IIA (microscopic transcap-
sular invasion) and IIB (macroscopic invasion into the
surrounding mediastinal fat tissue or nontransmural
adherence to the mediastinal pleura) was specifically
designed to indicate the need for postoperative RT, and
it seems, therefore, superior to the standard Masaoka
system. Nonetheless, 40% of the centers stated that they
do not use RT after resection of stage II thymoma. This
leaves field to an open discussion, but an answer will be
able only through prospective randomized trials.
On the other hand, there is an almost unanimous con-
sensus concerning postoperative treatment after resec-
tion (either complete or not) of stage III thymoma.
There are, however, three centers stating that they do
not administer any postoperative treatment in case of
complete resection; incomplete resection poses indication
to RT. Postoperative chemotherapy alone is rarely admin-
istered, and in most of the cases, the association of
chemo-RT or RT alone seems preferable. Also, the inter-
national literature reflects the impossibility to standardize
this approach as results with postoperative administration
of RT have never been analyzed in prospective trials, and
cases with and without postoperative treatment are usually
mixed in the reports without any rule.
The interpretation of the results concerning induction
treatment for stage III tumors is easier; this treatment
modality is clearly accepted in the international litera-
ture3,33–35 in case of invasive tumors potentially unre-
sectable, and this is what was also performed by most of
the centers answering the survey.
6. Treatment of stage IVA thymoma, recurrence, and type
C thymoma: Masaoka stage IVA is a challenging situ-
ation. The indolent biologic behavior of thymoma and
the predictable response to chemotherapy encourage to
seek long-term survival without surgery36,37; on the
other hand, recent reports support an increasing evi-
dence that complete resection of pleural implants, along
with mediastinal dissection and even EPP is effective in
prolonging disease-free survival in this subset of pa-
tients.38–42 Interestingly, most of the centers agree to
consider surgery for stage IVA thymoma, and almost all
administer induction chemotherapy before resection.
Approximately 40% perform EPP or P/D to achieve a
complete macroscopic resection of the pleural implants.
The remaining centers rely on discrete resection of
pleural metastases, and only one center use intracavitary
hyperthermic chemotherapy. It is clear that there is a
tendency toward a more aggressive attitude in stage
IVA thymoma, although most of the EPP were per-
formed at “high volume” institutions.
Concerning locoregional recurrence, there is no doubt
from the recent literature that surgery plays a major role
in a multidisciplinary approach.42–46 Reresections are
also indicated in case of subsequent recurrences. Also,
as most centers correctly pointed out, a proper patient
selection is crucial, as incomplete resection of recur-
rence is a poor prognostic factor.
Management of thymic carcinoma is not standardized in
the literature,47–50 and this clearly emerges also from
our survey. Half the centers reported to approach type C
thymoma similarly to other types of thymoma, whereas
the remaining half indicated that they use a completely
different protocol. The latter group added in their com-
ments that they always perform a multidisciplinary
approach with induction therapy (chemotherapy or
combined chemo-RT) even in apparently completely
resectable disease or stage I tumors and use a different
chemotherapeutic schedule (however, this was not re-
ported in the comments). Once again, this issue needs to
be further clarified as conflicting practice exists even
among experienced centers.
7. Multidisciplinary organization and logistics: There is a
clear evidence that almost all centers support the idea of
a dedicated team including thoracic surgeons, patholo-
gists, medical, and a radiation oncologists experienced
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in this field. Most centers pointed out that all cases
should be discussed in a dedicated tumor board.
8. High-volume and low-volume centers: Interestingly,
management of thymic malignancies looks quite similar
at high- and low-volume centers. The most important
difference consists in the use of preoperative and post-
operative treatments at stage II and III disease. High-
volume centers tend not to use RT after resection of
stage II thymoma, and they tend to rely more on
postoperative RT than combined chemo-RT after resec-
tion of stage III tumors. The relatively small number of
centers answering the questionnaire suggests a word of
caution in the interpretation of these results, which
surely deserve confirmation in a larger sample size.
Survey studies have distinctive characteristics and sev-
eral limitations, and the present one is not an exception. A
limit of this study may be considered as the geographical
distribution among the centers and the issue of the represen-
tative among the ESTS community; it should be noted,
however, that the proposal of the project was offered by
e-mail to all the ESTS community, and all ESTS members
had, therefore, the opportunity to join the project; also, the
overrepresentation of Italian centers may result from the
longstanding tradition in the management of thymic neo-
plasms from Italian centers and the general interest in thymic
neoplasms in this country. Another important limitation is
related to the preparation of the list of questions. The ques-
tionnaire is made of close-ended questions, specifically de-
signed to be easy to understand, not time consuming, and
direct; this is crucial to obtain a high response rate. As a
consequence, some details are difficult to be extrapolated, and
the final result is, therefore, a general overview of the current
practice. A second limitation is that surveys are unavoidably
biased toward those who reply, ignoring those (usually most)
who do not answer for whatever reason (they do not perform
thymic surgery, they are not willing to participate, they
disagree with most of the questions, they have no time, etc.).
There are no data about how many ESTS members really
perform thymic surgery, and this represents a major bias. A
third limitation results from the body of data: as the ques-
tionnaire is filled out with “self-response” data, we do not
know how accurate and true they are, and theoretically, a
possible bias may result if the respondent simply tries to
adhere to the literature instead of reporting his/her true
clinical practice. Finally, it should be emphasized that the
results of a survey are not to be taken as a recommendation,
as they lack the required statistical validation from the very
beginning.
On the other hand, the value of the present survey is
that it represents a large, multiinstitutional, clear, comprehen-
sive overview of the clinical practice in the management of
thymic tumors. It is an up-to-date picture of the state of the
art. An added value of this study includes the possibility to
identify areas of agreement and areas where a considerable
debate remains because of the variability in the responses. As
a consequence, it provides a stimulus to identify specific
issues needing further discussion, to prompt retrospective
studies in areas of controversy, to design prospective studies
on specific areas of interest, and, finally, to form the back-
bone to set up guidelines and recommendations.
In conclusion, the present survey from the ESTS-TWG
is currently the largest report concerning the overall approach
to this disease so far. The next move will be the creation of
a collaborative effort within the ESTS and with other orga-
nizations for research projects, to eventually achieve stan-
dardized guidelines.
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